KPV FDA Review: What the July Vote Really Changed

The KPV FDA review did not approve KPV or add it to a federal compounding list. KPV has never had an FDA-approved U.S. product. What happened in July 2026 was narrower: an outside advisory committee recommended that FDA place two forms of KPV on the 503A Bulks List. FDA still has to make the decision through rulemaking.

That may sound like paperwork, but it is the difference between a recommendation and a rule. Here is how the review reached that point.

How the KPV FDA review began

KPV is a tripeptide, meaning a chain of three amino acids: lysine, proline and valine. It is the three-amino-acid tail of alpha-melanocyte-stimulating hormone, or alpha-MSH.

Wells Pharmacy Network nominated KPV for the 503A Bulks List, the federal list of starting ingredients that may qualify for use in patient-specific compounded medicines when the other ingredient routes in the law do not apply. The public docket says FDA received the nomination on March 25, 2021, and posted it on April 1.

The submission proposed a 0.1% cream or gel for wound healing and inflammatory conditions. It was unclear whether the nominee meant KPV free base or KPV acetate, two related but distinct chemical forms. FDA eventually chose to review both. Nomination began an evaluation; it did not put either form on the list.

Category 2, then a withdrawn nomination

FDA placed KPV in Category 2 in September 2023. Category 2 was an interim policy bucket for nominated ingredients that the agency believed raised significant safety concerns. It was not a final rule and it was not a drug-approval decision.

The nominator withdrew KPV and 11 other peptide nominations on April 14, 2026, according to the withdrawal record. FDA’s nominations document, marked “Updated May 14, 2026,” no longer shows KPV in Category 2. It is not in Category 1 or Category 3 either. Withdrawal removed the nomination from those working categories; it did not add KPV to the 503A Bulks List.

FDA nevertheless continued the review on its own initiative. That is why a withdrawn nomination still reached an advisory meeting.

What FDA staff said about the evidence

FDA’s May 12, 2026 briefing document recommended against listing either KPV form. Staff said the nomination mixed up the free base and acetate in places, did not provide enough quality information about impurities and peptide clumping, and did not establish how the proposed cream or gel would perform.

The human-data finding was even plainer. FDA found no clinical study or human exposure data for KPV by any route. It also found no human study of pharmacokinetics, meaning how the body absorbs, moves and clears a substance.

The research FDA did find was preclinical, meaning work in cells or animals. A 2008 study reported that KPV entered cultured intestinal and immune cells through a peptide transporter and lowered inflammatory signals; the same paper tested two mouse colitis models (Dalmasso et al., Gastroenterology). Another 2008 paper reported less inflammatory change in two mouse colitis models (Kannengiesser et al., Inflammatory Bowel Diseases). Neither was a trial in patients. The KPV evidence guide covers those experiments in detail.

FDA also raised immunogenicity, an unwanted immune response. Peptides can clump together, and those aggregates or manufacturing impurities can affect immune risk. Staff did not say that a known percentage of people would have a reaction. It said the human data needed to estimate that risk did not exist.

The committee voted against the staff recommendation

KPV came before the Pharmacy Compounding Advisory Committee on July 23, 2026. PCAC is an outside panel that advises FDA; its recommendations are not binding.

The official agenda scheduled an open public hearing, followed by presentations from FDA reviewers Emily Kneeream, PharmD, Jing Li, PhD, and Nga-Lai Poon, PharmD. Staff presented its case against adding KPV free base and KPV acetate.

The committee went the other way. The official FDA recording displays 8 yes votes, 6 no votes and 1 abstention for the KPV recommendation. FDA has posted no written tally or meeting minutes, so the recording is the primary record of the count. The panel recommended inclusion; it did not itself change the list. Our overview of the July peptide decision puts that vote beside the six other peptide reviews.

Where the rulemaking stands now

As of September 18, 2026, the day this article was written, FDA’s current 503A nominations document is still marked “Updated May 14, 2026,” does not place KPV in a category, and the agency has published no proposed or final rule adding KPV to the 503A Bulks List. The July vote remains advice.

One fresh study does not change that status or close the human-data gap. A paper published online August 9, 2026 tested KPV in cultured mouse fat cells and in mice fed a high-fat diet; it reported changes in fat-cell development and metabolic measures, not outcomes in people (An et al., Tissue and Cell). It arrived after FDA’s May staff review and remains preclinical.

The next record that would matter is a proposed rule, followed by public comment and a final rule. There is no published deadline.

What the vote does and does not change for KLOW

KPV is one ingredient in Promise’s KLOW blend. The committee reviewed KPV free base and KPV acetate as starting ingredients for wound healing and inflammatory conditions. It did not review the finished KLOW blend, its other three ingredients or a specific patient’s prescription.

A favorable ingredient-list recommendation also does not make KPV FDA-approved or prove a benefit. The separate guide to KPV peptide benefits explains why cell and mouse findings cannot supply a human effect size, dose or safety rate.

Regulatory review status is never a marketing gate. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. A prescription by itself does not settle whether a pharmacy can prepare and dispense a particular formulation under the federal and state rules that apply.

What belongs in the prescription conversation

The useful questions are concrete: which KPV form and route are being considered, what the pharmacy can document about the ingredient and finished preparation, what human evidence is missing, and how the provider would follow safety. The July vote cannot answer those questions for one person.

At Promise, a licensed provider reviews every request and not everyone qualifies. That review weighs medical history, current medications, the requested formulation and the uncertainty in the evidence before any prescription decision.